Beam Therapeutics’ $120 Million Acquisition of GuideTx

Orrick Herrington & Sutcliffe LLP advised Guide Therapeutics on the deal.

Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, announced its acquisition by biotech company Beam Therapeutics.

Under the terms of the merger agreement, Beam paid upfront consideration of $120 million, excluding customary purchase price adjustments, in Beam common stock.

In addition to the upfront payment, GuideTx stockholders will be eligible to receive up to an additional $320 million in technology and product success milestone payments, payable in Beam common stock. Additional financial details were not disclosed.

Beam Therapeutics Inc. operates as a biotechnology company. The Company develops DNA base editing technologies for the treatment of human diseases.

The Orrick team advising GuideTx was led by David Schulman (Picture) and includes Eric Wall, David Gold, Michael Wiesner, Mark Mushkin, Heather Behrend, Davis Doherty, Yuan Tian and Karen Cannon.

Involved fees earner: Heather Behrend – Orrick; Karen Cannon – Orrick; Davis Doherty – Orrick; David Gold – Orrick; Mark Mushkin – Orrick; David Schulman – Orrick; Eric Wall – Orrick; Michael Wiesner – Orrick;

Law Firms: Orrick;

Clients: Guide Therapeutics;

Martina Bellini

Author: Martina Bellini